177Lu-PNT6555 (part of the PNT2004 development program) is a molecule from the FAPi family developed as a therapeutic agent for the treatment of FAP-expressing tumors. The drug is developed in parallel with the companion PET Imaging agent 68Ga-PNT6555.
A clinical trial (Phase I) was initiated in June 2022.

Target/Mechanism: Fibroblasts

Carrier/Ligand: FAPi

Radiation Type: beta electrons (β)